{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T04:29:30Z","timestamp":1793075370800,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Cardiovascular Interventions"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jcin.2025.11.029","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T19:30:31Z","timestamp":1770665431000},"page":"283-296","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Genotype-Guided vs Conventional Oral P2Y12 Inhibitors in Acute Coronary Syndrome"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3909-182X","authenticated-orcid":false,"given":"Mattia","family":"Galli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3813-3469","authenticated-orcid":false,"given":"Naveen L.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan J.","family":"Lennon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4083-9957","authenticated-orcid":false,"given":"Wout W.A.","family":"van den Broek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.F.","family":"Claassens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas O.","family":"Bergmeijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2407-7435","authenticated-orcid":false,"given":"Luca","family":"Fazzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera H.M.","family":"Deneer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Hassan","family":"Murad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Farkouh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charanjit","family":"Rihal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5192-886X","authenticated-orcid":false,"given":"Jurrien","family":"ten Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick J.","family":"Angiolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcin.2025.11.029_bib1","doi-asserted-by":"crossref","first-page":"e1371","DOI":"10.4244\/EIJ-D-21-00904","article-title":"Antiplatelet therapy after percutaneous coronary intervention","volume":"17","author":"Angiolillo","year":"2022","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jcin.2025.11.029_bib2","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2025.11.029_bib3","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jacc.2021.09.006","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Lawton","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2025.11.029_bib4","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcin.2025.11.029_bib5","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcin.2025.11.029_bib6","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jcin.2021.01.024","article-title":"Effect of CYP2C19 genotype on ischemic outcomes during oral P2Y(12) inhibitor therapy: a meta-analysis","volume":"14","author":"Pereira","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2025.11.029_bib7","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/eurheartj\/ehv104","article-title":"Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention","volume":"36","author":"Aradi","year":"2015","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.jcin.2025.11.029_bib8","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.120.009434","article-title":"Clopidogrel versus ticagrelor or prasugrel after primary percutaneous coronary intervention according to CYP2C19 genotype","volume":"14","author":"Claassens","year":"2021","journal-title":"Circ Cardiovasc Interv"},{"issue":"22","key":"10.1016\/j.jcin.2025.11.029_bib9","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1016\/j.jcin.2024.08.027","article-title":"International consensus statement on platelet function and genetic testing for guiding oral P2Y12 inhibitor treatment in percutaneous coronary intervention: 2024 update","volume":"17","author":"Angiolillo","year":"2024","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2025.11.029_bib10","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.jacc.2024.06.038","article-title":"Genotype-guided antiplatelet therapy: JACC review topic of the week","volume":"84","author":"van den Broek","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2025.11.029_bib11","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41569-021-00549-w","article-title":"Pharmacogenetics to guide cardiovascular drug therapy","volume":"18","author":"Duarte","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jcin.2025.11.029_bib12","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.119.007811","article-title":"Clopidogrel pharmacogenetics","volume":"12","author":"Pereira","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2025.11.029_bib13","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1161\/CIRCULATIONAHA.109.851949","article-title":"Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes","volume":"119","author":"Mega","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2025.11.029_bib14","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S0140-6736(10)61273-1","article-title":"Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis","volume":"376","author":"Mega","year":"2010","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.jcin.2025.11.029_bib15","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1056\/NEJMoa1008410","article-title":"Effects of CYP2C19 genotype on outcomes of clopidogrel treatment","volume":"363","author":"Par\u00e9","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcin.2025.11.029_bib16","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.jcin.2025.11.029_bib17","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1907096","article-title":"A genotype-guided strategy for oral P2Y(12) inhibitors in primary PCI","volume":"381","author":"Claassens","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jcin.2025.11.029_bib18","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.2020.12443","article-title":"Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial","volume":"324","author":"Pereira","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2025.11.029_bib19","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/sim.7141","article-title":"Meta-analysis using individual participant data: one-stage and two-stage approaches, and why they may differ","volume":"36","author":"Burke","year":"2017","journal-title":"Stat Med"},{"key":"10.1016\/j.jcin.2025.11.029_bib20","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/CIRCULATIONAHA.123.064473","article-title":"Defining strategies of modulation of antiplatelet therapy in patients with coronary artery disease: a consensus document from the Academic Research Consortium","volume":"147","author":"Capodanno","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2025.11.029_bib21","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/sim.7171","article-title":"One-stage individual participant data meta-analysis models: estimation of treatment-covariate interactions must avoid ecological bias by separating out within-trial and across-trial information","volume":"36","author":"Hua","year":"2017","journal-title":"Stat Med"},{"key":"10.1016\/j.jcin.2025.11.029_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcin.2024.06.020","article-title":"Real-world implementation of a genotype-guided P2Y12 inhibitor de-escalation strategy in acute coronary syndrome patients.","author":"Azzahhafi","year":"2024","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2025.11.029_bib23","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jcin.2020.01.219","article-title":"Routine CYP2C19 genotyping to adjust thienopyridine treatment after primary PCI for STEMI: results of the GIANT study","volume":"13","author":"Hulot","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"issue":"6","key":"10.1016\/j.jcin.2025.11.029_bib24","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1161\/CIR.0000000000001257","article-title":"CYP2C19 genetic testing for oral P2Y12 inhibitor therapy: a scientific statement from the American Heart Association","volume":"150","author":"Pereira","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2025.11.029_bib25","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/cpt.2526","article-title":"Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update","volume":"112","author":"Lee","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jcin.2025.11.029_bib28","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/S0140-6736(21)00533-X","article-title":"Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis","volume":"397","author":"Galli","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jcin.2025.11.029_bib29","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/eurheartj\/ehab836","article-title":"Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials","volume":"43","author":"Galli","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2025.11.029_bib30","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1056\/NEJMra1607714","article-title":"Management of antithrombotic therapy after acute coronary syndromes","volume":"384","author":"Rodriguez","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcin.2025.11.029_bib31","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41569-023-00901-2","article-title":"De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a consensus statement from an international expert panel on coronary thrombosis","volume":"20","author":"Gorog","year":"2023","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"10.1016\/j.jcin.2025.11.029_bib32","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/ehjcvp\/pvae087","article-title":"Cost-effectiveness of implementing a genotype-guided de-escalation strategy in patients with acute coronary syndrome","volume":"11","author":"van den Broek","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jcin.2025.11.029_bib33","doi-asserted-by":"crossref","first-page":"221","DOI":"10.7326\/M13-1999","article-title":"Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome","volume":"160","author":"Kazi","year":"2014","journal-title":"Ann Intern Med"}],"container-title":["JACC: Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879825031784?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879825031784?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T19:30:48Z","timestamp":1770665448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936879825031784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1936879825031784"],"URL":"https:\/\/doi.org\/10.1016\/j.jcin.2025.11.029","relation":{},"ISSN":["1936-8798"],"issn-type":[{"value":"1936-8798","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genotype-Guided vs Conventional Oral P2Y12 Inhibitors in Acute Coronary Syndrome","name":"articletitle","label":"Article Title"},{"value":"JACC: Cardiovascular Interventions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcin.2025.11.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 the American College of Cardiology Foundation. Published by Elsevier. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}